The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis
Inflammopharmacology · 2025
DOI: 10.1007/s10787-025-01735-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Huaixuan Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. Hauptthemen laut MEDLINE: Hydroxychloroquine, Arthritis, Rheumatoid, Blood Glucose, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Key Research and Development Projects of Anhui Province.
Abstract (Originalsprache)
OBJECTIVE: To explore the potential combined effects of hydroxycholoroquine (HCQ) and its metabolites on blood lipids and glucose in the treatment of rheumatoid arthritis (RA). METHODS: In the HCQ group, the concentrations of HCQ and its metabolites, including desethylhydroxychloroquine (DHCQ), esethylchloroquine (DCQ) and bisdesethylchloroquine (BDCQ), were detected by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The relationships between the levels of blood lipid and glucose and concentrations of HCQ and its metabolites were also analysed. Further, a multiple regression model was employed to evaluate the actual roles of HCQ and its metabolites in various factors affecting blood lipids and glucose. RESULTS: Significant higher high-density lipoprotein cholesterol (HDL) and lower low-density lipoprotein cholesterol (LDL) are found in the HCQ group than in the control group [1.63 ± 0.39 mmol/l vs. 1.39 ± 0.35 mmol/l, p < 0.001; 2.15 (1.80, 2.81) mmol/l vs. 2.54 (2.24, 3.10) mmol/l, p = 0.017, respectively]. Multivariate regression analysis indicates only HCQ concentration might act as an independent factor influencing the levels of HDL, VLDL, and TG in RA patients. CONCLUSION: HCQ might increase HDL level and reduce LDL, VLDL, TC, and TG levels in RA treatment. These beneficial effects on modifying lipid profile might be counteracted to various degrees by some of its metabolites (DHCQ and BDCQ). Therefore, for RA patients with HCQ in their treatment regime, it might facilitate the improvement of lipids profile by promoting the excretion of HCQ metabolites. This study did not demonstrate the significant hypoglycemic effect of HCQ and its metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. amushuaizw@163.com.
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, 230032, China. amushuaizw@163.com.
Förderung
- The Key Research and Development Projects of Anhui Province
Zitieren
APA
Zhang, H., Wu, X., Wang, Y., Yang, Z., Dai, Y., & Shuai, Z. (2025). The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01735-9
Vancouver
Zhang H, Wu X, Wang Y, Yang Z, Dai Y, Shuai Z. The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01735-9
BibTeX
@article{Zhang2025,
author = {Zhang, Huaixuan and Wu, Xueting and Wang, Yue and Yang, Zhongling and Dai, Yaqian and Shuai, Zongwen},
title = {The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis},
journal = {Inflammopharmacology},
year = {2025},
doi = {10.1007/s10787-025-01735-9}
}
EUVIMED